JP5715420B2 - 抗ヘッジホッグ抗体 - Google Patents

抗ヘッジホッグ抗体 Download PDF

Info

Publication number
JP5715420B2
JP5715420B2 JP2010540846A JP2010540846A JP5715420B2 JP 5715420 B2 JP5715420 B2 JP 5715420B2 JP 2010540846 A JP2010540846 A JP 2010540846A JP 2010540846 A JP2010540846 A JP 2010540846A JP 5715420 B2 JP5715420 B2 JP 5715420B2
Authority
JP
Japan
Prior art keywords
hedgehog
antibody
tissue
cells
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010540846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511762A5 (enExample
JP2011511762A (ja
Inventor
スザンナ ジェイ． スケールズ，
スザンナ ジェイ． スケールズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2011511762A publication Critical patent/JP2011511762A/ja
Publication of JP2011511762A5 publication Critical patent/JP2011511762A5/ja
Application granted granted Critical
Publication of JP5715420B2 publication Critical patent/JP5715420B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010540846A 2007-12-28 2008-12-22 抗ヘッジホッグ抗体 Expired - Fee Related JP5715420B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1723207P 2007-12-28 2007-12-28
US61/017,232 2007-12-28
US9986408P 2008-09-24 2008-09-24
US61/099,864 2008-09-24
PCT/US2008/088059 WO2009086324A1 (en) 2007-12-28 2008-12-22 Anti-hedgehog antibodies

Publications (3)

Publication Number Publication Date
JP2011511762A JP2011511762A (ja) 2011-04-14
JP2011511762A5 JP2011511762A5 (enExample) 2012-02-16
JP5715420B2 true JP5715420B2 (ja) 2015-05-07

Family

ID=40433914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010540846A Expired - Fee Related JP5715420B2 (ja) 2007-12-28 2008-12-22 抗ヘッジホッグ抗体

Country Status (7)

Country Link
US (3) US8030454B2 (enExample)
EP (1) EP2235063B1 (enExample)
JP (1) JP5715420B2 (enExample)
AU (1) AU2008345246B2 (enExample)
CA (1) CA2709399C (enExample)
ES (1) ES2551736T3 (enExample)
WO (1) WO2009086324A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573832B (zh) * 2009-08-25 2015-07-22 阿布拉科斯生物科学有限公司 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
PH12022550313A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
US11867696B2 (en) * 2015-02-06 2024-01-09 Cell Idx, Inc. Antigen-coupled immunoreagents
CN104645358A (zh) * 2015-02-09 2015-05-27 中国人民解放军第二军医大学 一种胰腺癌靶向的纳米级超声造影剂及其制备方法和应用
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN112805299B (zh) 2018-10-05 2025-09-16 西雅图儿童医院以西雅图儿童研究机构名义经营 针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查
US11940448B2 (en) 2020-03-31 2024-03-26 Seattle Children's Hospital Proteomic screening for lysosomal storage diseases
US12523662B2 (en) 2020-04-02 2026-01-13 Seattle Children's Hospital Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US7060450B1 (en) * 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
JPH114695A (ja) * 1997-04-25 1999-01-12 Hayashibara Biochem Lab Inc ヘッジホッグ蛋白質
AU767066B2 (en) * 1999-03-03 2003-10-30 Curis, Inc. Methods of modulating lipid metabolism and storage
IL153115A0 (en) * 2000-06-16 2003-06-24 Curis Inc Angiogenesis-modulating compositions and uses
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
CA2425356C (en) * 2000-10-13 2015-10-06 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
ES2707393T3 (es) * 2004-03-26 2019-04-03 Curis Inc Moduladores de interferencia de ARN de señalización de hedgehog y usos de los mismos

Also Published As

Publication number Publication date
EP2235063A1 (en) 2010-10-06
AU2008345246A1 (en) 2009-07-09
EP2235063B1 (en) 2015-09-02
ES2551736T3 (es) 2015-11-23
CA2709399C (en) 2021-01-19
AU2008345246B2 (en) 2014-08-07
US8030454B2 (en) 2011-10-04
CA2709399A1 (en) 2009-07-09
US20130011853A1 (en) 2013-01-10
US20100003239A1 (en) 2010-01-07
JP2011511762A (ja) 2011-04-14
US20120028829A1 (en) 2012-02-02
HK1146595A1 (zh) 2011-06-24
WO2009086324A1 (en) 2009-07-09
US8338112B1 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
JP5715420B2 (ja) 抗ヘッジホッグ抗体
Lodyga et al. Cadherin-11–mediated adhesion of macrophages to myofibroblasts establishes a profibrotic niche of active TGF-β
US7915390B2 (en) Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
US20210269549A1 (en) Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
JP2006517109A (ja) アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
JP2006517109A5 (enExample)
RU2447449C2 (ru) Модуляторы нейрональной регенерации
EP1978973B1 (en) Use hedgehog kinase antagonists to inhibit hedgehog signaling and to treat cancer
JP5319051B2 (ja) Ａ３３抗原およびｊａｍ−ｉｔの使用
JP2006501862A5 (enExample)
CN101971034A (zh) 神经元再生的调控剂
JP2009510002A (ja) 反発誘導分子（ｒｇｍ）タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
JP2010511060A (ja) 神経膠腫の診断及び治療方法
JP2021073928A (ja) 免疫関連細胞の一次繊毛の調整方法および調整剤、並びに、試験試料の評価方法
WO2023285878A1 (en) Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
AU2007243946B2 (en) Method for using BOC/CDO to modulate hedgehog signaling
HK1146595B (en) Anti-hedgehog antibodies
JP2008261764A (ja) キナーゼ阻害物質の測定方法
AU2013204025A1 (en) Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150313

R150 Certificate of patent or registration of utility model

Ref document number: 5715420

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees